MedDataX Logo

Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis

NCT ID: NCT00565279

Last Updated: 2008-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. This study will test the efficacy and safety of ASF1057 in the treatment of patients with seborrhoeic dermatitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seborrheic Dermatitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Seborrhoeic dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ASF1057

Group Type EXPERIMENTAL

ASF1057

Intervention Type DRUG

Twice daily, topical

ASF1057

Intervention Type DRUG

Twice daily, Topical

ASF1057 placebo

Group Type PLACEBO_COMPARATOR

ASF1057

Intervention Type DRUG

Twice daily, topical

ASF1057

Intervention Type DRUG

Twice daily, Topical

ASF1057 Vehicle

Group Type PLACEBO_COMPARATOR

ASF1057

Intervention Type DRUG

Twice daily, topical

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ASF1057

Twice daily, topical

Intervention Type DRUG

ASF1057

Twice daily, Topical

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of moderate to severe seborrhoeic dermatitis

Exclusion Criteria

* Other active skin diseases
* Use of certain systemic and topical treatments
* Extensive sun exposure
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Astion Pharma A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Astion Pharma A/S

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peder M Andersen, MD

Role: STUDY_DIRECTOR

Astion Pharma A/S

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ASF1057-301

Identifier Type: -

Identifier Source: org_study_id